Drugs / MK-0893
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT00902161 | May → Oct 2009 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 1 | NCT02012166 | Jul → Dec 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT00631488 | Feb 2008 → Jan 2009 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 2 | NCT00479466 | Jul 2007 → May 2008 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | Met primary |
| Phase 2 | NCT02004886 | Aug 2006 → Feb 2007 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0893 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02004886 ↗ |
| Action | Inhibit | “Glucagon receptor antagonist” CHEMBL1933349 ↗ |
| Modality | Small molecule | — CHEMBL1933349 ↗ |
| Route | Oral | “MK0893 taken orally once daily” NCT00479466 ↗ |
| Target | GCGR | “Glucagon receptor antagonist” CHEMBL1933349 ↗ |